Open access
Jul 2026
Abbapolin inhibitors of the PLK1 PBD as Prostate Cancer Therapeutics, in vivo activity and synergy with androgen therapy
These studies establish selective inhibition of the PLK1 Polo-box domain as a viable therapeutic strategy, provide in vivo proof-of-concept for the REPLACE approach, and identify abbapolins as promising leads for advanced prostate cancer.
George Merhej, Gurusankar Ramamoorthy, Danda Chapagai et al.
· bioRxiv · 0 citations